Need Help?

RNA-seq analysis of metastatic prostate cancer solid tumor biopsies

The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)–targeting therapy. We sought to characterize the clinical and genomic features of t-SCNC in a multi-institutional prospective study. Patients with progressive, metastatic castration-resistant prostate cancer (mCRPC) underwent metastatic tumor biopsy and were followed for survival. t-SCNC is present in nearly one fifth of patients with mCRPC and is associated with shortened survival.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001008991 Illumina HiSeq 1500 118
EGAD00001009065 Illumina HiSeq 1500 Illumina HiSeq 4000 164
Publications Citations
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Cancer Res 83: 2023 2763-2774